Gilead Sciences, Inc. (GILD)
73.66 USD -1.93 (-2.55%) Volume: 9.54M
Gilead Sciences, Inc.’s stock price currently stands at 73.66 USD, marking a decrease of -2.55% this trading session, with a trading volume of 9.54M. The biopharmaceutical company’s stock has experienced a year-to-date decrease of -9.07%, reflecting its dynamic performance in the market.
Latest developments on Gilead Sciences, Inc.
Gilead Sciences, Inc. has been making waves in the market with its recent quarterly profit beating Street estimates and revenue increasing by 5%. The pharmaceutical giant is also set to ‘redefine’ the HIV PrEP market with the anticipated 2025 launch of the long-acting Sunlenca. In Q2 of 2024, Gilead reported a rise in net income, further solidifying its position in the industry. Despite underperforming the market, Gilead’s stock rose on Thursday following the strong quarterly results. With earnings surpassing expectations and revenue hitting $7.0 billion, Gilead continues to impress investors. Analysts have even raised the price target for Gilead stock to $85.00, reflecting confidence in the company’s future performance. Overall, Gilead Sciences remains a key player in the healthcare sector, driving innovation and growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars